Digital self-management package for people with interstitial lung disease
A Randomised Clinical Trial of a Digital Self-management Package for People With Interstitial Lung Disease
This study is testing a new smartphone app designed to help people with interstitial lung disease manage their health better and feel improved overall compared to standard care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Sydney Academic / other |
| Locations | 4 sites (Sydney, New South Wales and 3 other locations) |
| Trial ID | NCT06122233 on ClinicalTrials.gov |
What this trial studies
This clinical trial compares a digital self-management package called REBUILD-SM, which includes a smartphone app, to standard care for individuals with interstitial lung disease (ILD). Participants in the intervention group will receive support from healthcare professionals while tracking their health data and completing questionnaires through the app. The study aims to evaluate improvements in health-related quality of life, symptoms, anxiety, self-efficacy, and physical activity over time. The control group will use a limited version of the app without the full self-management support.
Who should consider this trial
Good fit: Ideal candidates are individuals diagnosed with fibrotic interstitial lung disease who possess a smartphone and have adequate digital literacy.
Not a fit: Patients who do not own a smartphone or lack the necessary digital literacy may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance the quality of life and self-management capabilities for patients with interstitial lung disease.
How similar studies have performed: Other studies have shown promise in using digital health interventions for chronic disease management, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of fibrotic ILD * In possession of a smartphone/tablet and an email address * Able to understand written and spoken English * Adequate digital literacy to complete requirements of trial * On stable ILD treatment for 30 days prior to enrolment Exclusion Criteria: * Not in possession of a smartphone/tablet * Insufficient digital literacy to complete requirements of trial * Unable to communicate in written/spoken English * Not on stable ILD treatment for 30 days prior to enrolment * Acute exacerbation within 30 days prior to enrolment * Participating in pulmonary rehab at enrolment or during 12-week intervention period * Unable to provide informed consent
Where this trial is running
Sydney, New South Wales and 3 other locations
- Royal Prince Alfred Hospital — Sydney, New South Wales, Australia (Recruiting)
- The Prince Charles Hospital — Brisbane, Queensland, Australia (Recruiting)
- Alfred Hospital — Melbourne, Victoria, Australia (Recruiting)
- Austin Health — Melbourne, Victoria, Australia (Recruiting)
Study contacts
- Principal investigator: Tamera Corte — University of Sydney
- Study coordinator: Carly Barton
- Email: Carly.Barton@Sydney.edu.au
- Phone: +61 2 9515 5682
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.